Lung cancer Cell Models for Research

Lung cancer is the leading cause of cancer-related mortality worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020 (WHO GLOBOCAN). The two main subtypes are non-small cell lung cancer (NSCLC, ~85%) and small cell lung cancer (SCLC, ~15%). The overall 5-year survival rate for lung cancer is only 22% (NCI SEER), but it varies significantly by stage: localized disease has a 63% 5-year survival, regional 35%, and distant 7%. Major risk factors include tobacco smoking, radon exposure, occupational carcinogens, and air pollution. The high mortality and heterogeneity underscore the urgent need for improved models to study tumor biology and develop targeted therapies.

Lung cancer is an ideal model for mechanistic studies due to its well-characterized molecular subtypes, extensive public genomic datasets (TCGA, COSMIC), and the presence of actionable oncogenic drivers (EGFR, ALK, KRAS, ROS1, BRAF, MET, RET, NTRK). Open questions include resistance mechanisms to targeted therapies, the role of tumor heterogeneity, and the development of effective immunotherapies. Gene-edited cell models enable precise dissection of these pathways and facilitate drug discovery.

Lung cancer arises from the accumulation of genetic and epigenetic alterations that activate oncogenes and inactivate tumor suppressors. Key pathways include:

• • EGFR signaling: Ligand binding induces receptor dimerization and autophosphorylation, activating downstream pathways such as RAS/MAPK, PI3K/AKT, and JAK/STAT, promoting cell proliferation and survival. Mutations in EGFR (exon 19 deletions, L858R) lead to constitutive activation.
• • KRAS signaling: KRAS is a small GTPase that cycles between active (GTP-bound) and inactive (GDP-bound) states. Mutations at codons 12, 13, or 61 impair GTP hydrolysis, locking KRAS in the active state, leading to uncontrolled activation of the MAPK and PI3K pathways.
• • ALK fusions: Chromosomal rearrangements (e.g., EML4-ALK) generate fusion proteins with constitutive kinase activity, driving oncogenic signaling through MAPK, PI3K, and JAK/STAT pathways.
• • TP53 pathway: TP53 is a tumor suppressor that regulates cell cycle arrest, apoptosis, and DNA repair. Loss-of-function mutations in TP53 are common and contribute to genomic instability.

The following table summarizes high-frequency genetic alterations in lung cancer based on TCGA and COSMIC data:

Key signaling networks deregulated in lung cancer include:

• • MAPK/ERK pathway: Activated by EGFR, KRAS, BRAF mutations, leading to cell proliferation and survival.
• • PI3K/AKT/mTOR pathway: Often activated via EGFR or loss of PTEN, promoting cell growth and metabolism.
• • JAK/STAT pathway: Activated by EGFR and ALK fusions, contributing to inflammation and immune evasion.
• • Wnt/β-catenin pathway: Deregulated in a subset of lung cancers, affecting cell differentiation and stemness.
• • Notch pathway: Involved in tumor initiation and maintenance, particularly in SCLC.

Commonly used lung cancer cell lines include:

Organoids derived from patient tumors retain the genetic heterogeneity and 3D architecture, making them valuable for drug testing and personalized medicine.

Animal models for lung cancer include:

• • Patient-derived xenografts (PDX): Tumor fragments implanted into immunodeficient mice, preserving the original tumor's genetic and histological features.
• • Genetically engineered mouse models (GEMM): Mice with inducible or constitutive expression of oncogenic drivers (e.g., KrasLSL-G12D; Trp53fl/fl) that develop lung tumors resembling human disease.
• • Induced models: Chemical carcinogens (e.g., urethane) or viral vectors (e.g., Ad-Cre) can induce lung tumors in mice.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise genetic modifications, such as knockouts (KO), knock-ins (KI), and point mutations. These models are essential for studying gene function and drug response in a controlled genetic background. For example:

• • TP53 knockout lines: A549 or NCI-H1299 cells with TP53 knocked out to study p53 loss-of-function effects.
• • EGFR T790M knock-in lines: NCI-H1975 cells with the T790M mutation introduced to model acquired resistance to first-generation EGFR inhibitors.
• • KRAS G12C knock-in lines: A549 cells with the G12C mutation introduced to test KRAS inhibitors.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing validated models with minimal off-target effects. These models are widely used in drug discovery, functional genomics, and target validation.

Gene-edited cell lines enable the validation of candidate oncogenes and tumor suppressors. For example:

• • Knockout of tumor suppressors: TP53 KO lines are used to study the impact on cell cycle, apoptosis, and DNA repair.
• • Knock-in of oncogenic mutations: EGFR L858R knock-in lines are used to study the activation of downstream signaling and sensitivity to EGFR inhibitors.
• • CRISPR screens: Genome-wide knockout libraries can be applied to identify genes essential for cell survival or drug resistance.

Isogenic pairs (wild-type vs. mutant) are powerful tools for drug screening. For example:

• • EGFR T790M knock-in lines: Used to test third-generation EGFR inhibitors (e.g., osimertinib) that target the T790M resistance mutation.
• • KRAS G12C knock-in lines: Used to evaluate KRAS G12C inhibitors (e.g., sotorasib) and identify resistance mechanisms.
• • Resistance modeling: Chronic exposure of cells to drugs can select for resistant clones, which can be analyzed to identify novel resistance mutations.

CRISPR-based synthetic lethality screens can identify vulnerabilities in cancer cells with specific genetic alterations. For example:

• • Synthetic lethal partners of KRAS: Screens in KRAS-mutant cells can identify genes whose knockdown is selectively lethal, providing new therapeutic targets.
• • Biomarker validation: Gene-edited cells can be used to validate candidate biomarkers for patient stratification and treatment response.